Scarcity of Donor Organs
The lack of availability of potential organs to transplant has been a major issue of concern. There is an ever-increasing demand for organ donors, and this demand is very high when compared to the actual supply. It has been estimated that, owing to the scarcity of donor organs, among all the patients who need organ transplantation, only 10% are able to undergo the process. In the United States, more than 119,000 patients are on the waiting list for organ transplantation. Around 22 patients die each year, due to the lack of available organs for transplantation. In Europe, by the end of 2015, more than 143,000 patients were waiting for an organ transplantation. In this region, 18 patients die each year, due to lack of available organs for transplantation.
The increased incidence of disabilities and organ failures, technological advancements in the artificial organs sector, and rapidly aging population are some other drivers of the market.
Cost of the procedure is a major constraint for the artificial organ market. The high cost of these organs can be attributed to the production policies required to address the patients, taxpayers, and medical technology corporations. For instance, organ transplantation has several issues in the current market scenario, such as the policies for procurement, transplant tourism, organ trafficking, and others.
Additionally, fear of device malfunction and its consequences are also restraining the market’s growth.
North America to Dominate the Market
The global artificial organ market has been segmented by organ type and geography. By organ type, the market has been segmented into artificial heart, artificial kidney, artificial livers, artificial pancreas, and artificial lungs. By geography, it has been segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and South America.
Due to increased incidences of organ failures, disabilities, and scarcity in the availability of donor organs, recent technological advancements, and the rapid rise of the geriatric population, North America dominates the market.
Major Players- EDWARD LIFESCIENCES CORPORATION, ASAHI KASEI MEDICAL CO. LTD, JARVIK HEART INC., BOSTON SCIENTIFIC CORPORATION, COCHLEAR LIMITED, TOUCH BIONICS, OSSUR, MEDTRONIC INC., LIFENET HEALTH, amongst others.
Reasons to Purchase this Report
- Analysis of the global artificial organ market, with region-specific assessments and competition analysis on global and regional scales
- Analyzing various perspectives of the industry with the help of Porter’s five forces analysis
- The treatment type that is expected to dominate the market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3 months analyst support along with the Market Estimate sheet (in excel)
This report can be customized to meet your requirements..
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Market Overview
5.3 Porter’s Five Force Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Degree of Competition
5.3.4 Threat of Substitution
5.3.5 Threat of New Entrants
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Scarcity of Donor Organs
6.1.2 Increased Incidence of Disabilities and Organ Failures
6.1.3 Technological Advancements in the Artificial Organ Sector
6.1.4 Rapidly Aging Population
6.2 Market Restraints
6.2.1 Expensive Procedures
6.2.2 Fear of Device Malfunction and its Consequences
6.3.1 Emerging Application in Clinical Diagnostics and Proteomics
7. Market Segmentation
7.1 By Organ Type
7.1.1 Artificial Heart
220.127.116.11 Prosthetic Heart Valves
18.104.22.168 Ventricular Assist Devices
7.1.2 Artificial Kidney
7.1.3 Artificial Livers
22.214.171.124 Liver Dialysis
126.96.36.199 Bio artificial Liver Device (BAL)
188.8.131.52 Molecular Adsorbent Recirculation Systems (MARS)
184.108.40.206 Single Pass Albumin Dialysis (SPAD)
7.1.4 Artificial Pancreas
220.127.116.11 Insulin Pump
7.1.5 Artificial Lungs
18.104.22.168 Extracorporeal Membrane Oxygenation
22.214.171.124 Heart-Lung Machines
7.2 By Geography
7.2.1 North America
126.96.36.199 Rest of Europe (RoE)
7.2.3 Asia Pacific
188.8.131.52 South Korea
184.108.40.206 Rest of Asia Pacific
7.2.4 The Middle East & Africa
220.127.116.11 GCC Countries
18.104.22.168 South Africa
22.214.171.124 Rest of Middle East & Africa
7.2.5 South America
126.96.36.199 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisitions
8.2 Agreements, Collaborations & Partnerships
8.3 New Product Launches
9. Key Players
9.1 Edward Life sciences Corporation
9.2 Asahi Kasei Medical Co. Ltd
9.3 Jarvik Heart Inc.
9.4 Boston Scientific Corporation
9.5 Cochlear Limited
9.6 Touch Bionics
9.8 Medtronic Inc.
9.9 Lifenet Health
10. Future of the Market